Expression of myeloid differentiation factor 88 in neurons is not requisite for the induction of sickness behavior by interleukin-1β

Journal of Neuroinflammation

Daniel L Marks²  Anthony P Barnes³  Marek Szumowski³  Julia E Maxson¹  Biliana O Veleva-Rotse³  Aaron J Grossberg⁴  Theodore P Braun⁴ 

[1] Knight Cancer Institute, Oregon Health and Science University, Portland, OR, 97239, USA;Papé Family Pediatric Research Institute, Department of Pediatrics, Oregon Health and Science University, Mail Code L-481, 3181 SW Sam Jackson Park Rd., Portland, OR, 97239, USA;Papé Family Pediatric Research Institute, Oregon Health and Science University, Portland, OR, 97239, USA;MD/PhD Program, Oregon Health and Science University, Portland, OR, 97239, USA

关键词: Lethargy;    Cachexia;    IL-1β;    Hypothalamus;    Inflammation;    Cytokines;    MyD88;    Sickness behavior;   

Others  :  1160220
DOI  :  10.1186/1742-2094-9-229

 received in 2012-04-23, accepted in 2012-09-25,  发布年份 2012

【 摘 要 】

Background

Animals respond to inflammation by suppressing normal high-energy activities, including feeding and locomotion, in favor of diverting resources to the immune response. The cytokine interleukin-1 beta (IL-1β) inhibits normal feeding and locomotor activity (LMA) via its actions in the central nervous system (CNS). Behavioral changes in response to IL-1β are mediated by myeloid differentiation factor 88 (MyD88) in non-hematopoietic cells. It is unknown whether IL-1β acts directly on neurons or requires transduction by non-neuronal cells.

Methods

The Nestin-cre mouse was crossed with MyD88^lox mice to delete MyD88 from neurons and glia in the CNS (MyD88^ΔCNS). These mice were compared to total body MyD88KO and wild type (WT) mice. Mice had cannulae stereotactically placed in the lateral ventricle and telemetry transponders implanted into the peritoneum. Mice were treated with either intracerebroventricular (i.c.v.) IL-1β (10 ng) or vehicle. Food intake, body weight and LMA were continuously monitored for 24 h after treatment. I.c.v. tumor necrosis factor (TNF), a MyD88-independent cytokine, was used to control for normal immune development. Peripheral inflammation was modeled using intraperitoneal lipopolysaccharide (LPS). Groups were compared using two-way ANOVA with Bonferroni post-test. Efficacy of recombination was evaluated using tdTomato reporter mice crossed with the Nestin-cre mouse. MyD88 deletion was confirmed by Western blot.

Results

I.c.v. IL-1β treatment caused a significant reduction in feeding, body weight and LMA in WT mice. MyD88KO mice were protected from these changes in response to i.c.v. IL-1β despite having intact behavioral responses to TNF. Cre-mediated recombination was observed in neurons and astrocytes, but not microglia or endothelial cells. In contrast to MyD88KO mice, the behavioral responses of MyD88^ΔCNS mice to i.c.v. IL-1β or intraperitoneal (i.p.) LPS were indistinguishable from those of WT mice.

Conclusion

Sickness behavior is mediated by MyD88 and is dependent on the activity of cytokines within the brain. Our results demonstrate that MyD88 is not required in neurons or astrocytes to induce this behavioral response to IL-1β or LPS. This suggests that a non-Nestin expressing cell population responds to IL-1β in the CNS and transduces the signal to neurons controlling feeding and activity.

【 授权许可】

   
2012 Braun et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Dantzer R, Bluthé RM, Layé S, Bret-Dibat JL, Parnet P, Kelley KW: Cytokines and sickness behavior. Ann N Y Acad Sci 1998, 840:586-590.
• [2]Morley JE, Thomas DR, Wilson M-MG: Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006, 83:735-743.
• [3]Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O’Brien ME: Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004, 90:1905-1911.
• [4]Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL, Han HQ: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543.
• [5]Lampa J, Westman M, Kadetoff D, Agréus AN, Le Maître E, Gillis-Haegerstrand C, Andersson M, Khademi M, Corr M, Christianson CA, Delaney A, Yaksh TL, Kosek E, Svensson CI: Peripheral inflammatory disease associated with centrally activated IL-1 system in humans and mice. Proc Natl Acad Sci U S A 2012, 109:12728-12733.
• [6]Plata-Salamán CR, Sonti G, Borkoski JP, Wilson CD, French-Mullen JM: Anorexia induced by chronic central administration of cytokines at estimated pathophysiological concentrations. Physiol Behav 1996, 60:867-875.
• [7]Layé S, Gheusi G, Cremona S, Combe C, Kelley K, Dantzer R, Parnet P: Endogenous brain IL-1 mediates LPS-induced anorexia and hypothalamic cytokine expression. Am J Physiol Regul Integr Comp Physiol 2000, 279:R93-R98.
• [8]Ogimoto K, Harris MK Jr, Wisse BE: MyD88 is a key mediator of anorexia, but not weight loss, induced by lipopolysaccharide and interleukin-1 beta. Endocrinology 2006, 147:4445-4453.
• [9]Wisse BE, Ogimoto K, Tang J, Harris MK Jr, Raines EW, Schwartz MW: Evidence that lipopolysaccharide-induced anorexia depends upon central, rather than peripheral, inflammatory signals. Endocrinology 2007, 148:5230-5237.
• [10]Grossberg AJ, Zhu X, Leinninger GM, Levasseur PR, Braun TP, Myers MG, Marks DL: Inflammation-induced lethargy is mediated by suppression of orexin neuron activity. J Neurosci 2011, 31:11376-11386.
• [11]Grossberg AJ, Scarlett JM, Zhu X, Bowe DD, Batra AK, Braun TP, Marks DL: Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130. Endocrinology 2010, 151:606-616.
• [12]Scarlett JM, Jobst EE, Enriori PJ, Bowe DD, Batra AK, Grant WF, Cowley MA, Marks DL: Regulation of central melanocortin signaling by interleukin-1 beta. Endocrinology 2007, 148:4217-4225.
• [13]Scarlett JM, Zhu X, Enriori PJ, Bowe DD, Batra AK, Levasseur PR, Grant WF, Meguid MM, Cowley MA, Marks DL: Regulation of agouti-related protein messenger ribonucleic acid transcription and peptide secretion by acute and chronic inflammation. Endocrinology 2008, 149:4837-4845.
• [14]Serrats J, Schiltz JC, García-Bueno B, van Rooijen N, Reyes TM, Sawchenko PE: Dual roles for perivascular macrophages in immune-to-brain signaling. Neuron 2010, 65:94-106.
• [15]Ching S, Zhang H, Belevych N, He L, Lai W, Pu X-a, Jaeger LB, Chen Q, Quan N: Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J Neurosci 2007, 27:10476-10486.
• [16]Ridder DA, Lang M-F, Salinin S, Röderer J-P, Struss M, Maser-Gluth C, Schwaninger M: TAK1 in brain endothelial cells mediates fever and lethargy. J Exp Med 2011, 208:2615-2623.
• [17]Davis CN, Mann E, Behrens MM, Gaidarova S, Rebek M, Rebek J, Bartfai T: MyD88-dependent and -independent signaling by IL-1 in neurons probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. Proc Natl Acad Sci USA 2006, 103:2953-2958.
• [18]Kleinridders A, Schenten D, Könner AC, Belgardt BF, Mauer J, Okamura T, Wunderlich FT, Medzhitov R, Brüning JC: MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab 2009, 10:249-259.
• [19]Leinninger GM, Jo Y-H, Leshan RL, Louis GW, Yang H, Barrera JG, Wilson H, Opland DM, Faouzi MA, Gong Y, Jones JC, Rhodes CJ, Chua S Jr, Diano S, Horvath TL, Seeley RJ, Becker JB, Münzberg H, Myers MG Jr: Leptin acts via leptin receptor-expressing lateral hypothalamic neurons to modulate the mesolimbic dopamine system and suppress feeding. Cell Metab 2009, 10:89-98.
• [20]Kawai T, Adachi O, Ogawa T, Takeda K, Akira S: Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999, 11:115-122.
• [21]Lau LT, Yu AC: Astrocytes produce and release interleukin-1, interleukin-6, tumor necrosis factor alpha and interferon-gamma following traumatic and metabolic injury. J Neurotrauma 2001, 18:351-359.
• [22]Breder CD, Dinarello CA, Saper CB: Interleukin-1 immunoreactive innervation of the human hypothalamus. Science 1988, 240:321-324.
• [23]Marks DL, Ling N, Cone RD: Role of the central melanocortin system in cachexia. Cancer Res 2001, 61:1432-1438.
• [24]Ericsson A, Arias C, Sawchenko PE: Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1. J Neurosci 1997, 17:7166-7179.
• [25]Lazarus M, Yoshida K, Coppari R, Bass CE, Mochizuki T, Lowell BB, Saper CB: EP3 prostaglandin receptors in the median preoptic nucleus are critical for fever responses. Nat Neuroscie 2007, 10:1131-1133.
• [26]Shimomura Y, Inukai T, Kuwabara S, Shimizu H, Takahashi M, Sato N, Uehara Y, Tanaka Y, Kobayashi I: Both cyclooxygenase and lipoxygenase inhibitor partially restore the anorexia by interleukin-1 beta. Life Sci 1992, 51:1419-1426.
• [27]Johnson PM, Vogt SK, Burney MW, Muglia LJ: COX-2 inhibition attenuates anorexia during systemic inflammation without impairing cytokine production. Am JPhysiol Endocrinol Metab 2002, 282:E650-E656.
• [28]Konsman JP, Tridon V, Dantzer R: Diffusion and action of intracerebroventricularly injected interleukin-1 in the CNS. Neuroscience 2000, 101:957-967.
• [29]Braun TP, Zhu X, Szumowski M, Scott GD, Grossberg AJ, Levasseur PR, Graham K, Khan S, Damaraju S, Colmers WF, Baracos VE, Marks DL: Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. J Exp Med 2011, 208:2449-2463.
• [30]Lloyd CE, Palopoli M, Vary TC: Effect of central administration of interleukin-1 receptor antagonist on protein synthesis in skeletal muscle, kidney, and liver during sepsis. Metabolism 2003, 52:1218-1225.
• [31]Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S: Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity 1998, 9:143-150.